d-Penicillamine
Identifieur interne : 003049 ( Main/Exploration ); précédent : 003048; suivant : 003050d-Penicillamine
Auteurs : David A. JoyceSource :
- Bailliere's Clinical Rheumatology [ 0950-3579 ] ; 1990.
English descriptors
- Teeft :
- Accessory function, Aldehyde groups, American academy, Annals, Antinuclear antibody, Arthritis, Aurothiomalate, Bioavailability, Biochemical pharmacology, Biological fluids, British journal, Cessation, Chronic therapy, Clinica chimica acta, Clinical investigation, Clinical pharmacology, Clinical response, Clinical rheumatology, Collagen, Collagen metabolism, Collagen synthesis, Complement component, Cooh, Disease activity, Dismute superoxide, Disulphide, Disulphides, Dixon, Dos, Drug metabolism, Drug reactions, Drug toxicity, Drug withdrawal, Erythematosus, Excretion, Experimental animals, Experimental conditions, Experimental immunology, Free radicals, Functional groups, Gold salts, Gravis, Haematuria, High doses, Hyaluronic acid, Idiopathic myasthenia gravis, Immune complexes, Immune system, Inflammatory, Inflammatory activity, Internal medicine, Lower doses, Lupus, Lymphocyte, Lymphocyte reaction, Metabolism, Monocyte, Multicenter, Multicenter trial group, Myasthenia, Myasthenia gravis, Natural history, Natural killer cells, Other causes, Oxygen species, Penicillamine, Penicillamine therapy, Peripheral blood, Pharmacokinetics, Pharmacology, Plasma albumin, Platelet count, Poor sulphoxidizers, Proteinuria, Pulmonary fibrosis, Radiological progression, Reactive, Reactive oxygen species, Relative bioavailability, Renal, Renal function, Rheumatic, Rheumatic diseases, Rheumatism, Rheumatoid, Rheumatoid arthritis, Rheumatoid factor, Rheumatoid factors, Rheumatoid nodules, Rheumatology, Risk factors, Scandinavian journal, Sclerosis, Slow resolution, Sodium aurothiomalate, Soluble collagen, Sulphasalazine, Sulphoxidation status, Sulphydryl, Sulphydryl groups, Superoxide, Symmetrical disulphide, Syndrome, Synovial, Synovial fluid, Systemic lupus erythematosus, Systemic sclerosis, Taste disturbance, Therapy, Thiazolidine formation, Toxicity, Toxicity profile, Trace amounts, Transition metal, Untreated patients, Urinary excretion, Waring.
Abstract
Summary: d-Pen represents an effective treatment for a proportion of patients with RA and PSS. Its status in the treatment of juvenile RA is uncertain. The best results will be obtained by a skilful, careful physician maintaining careful surveillance for toxicity. Neither the mode of action nor the mechanisms of toxicity are well understood in RA. Consequently, safer and more effective analogues of d-pen have not been produced.
Url:
DOI: 10.1016/S0950-3579(05)80007-X
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000272
- to stream Istex, to step Curation: 000272
- to stream Istex, to step Checkpoint: 001E20
- to stream Main, to step Merge: 003118
- to stream Main, to step Curation: 003049
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">d-Penicillamine</title><author><name sortKey="Joyce, David A" sort="Joyce, David A" uniqKey="Joyce D" first="David A." last="Joyce">David A. Joyce</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CD2F2E69A770DA328B3768D12AB0105EB2A00060</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1016/S0950-3579(05)80007-X</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-F96WXBLC-L/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000272</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000272</idno><idno type="wicri:Area/Istex/Curation">000272</idno><idno type="wicri:Area/Istex/Checkpoint">001E20</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E20</idno><idno type="wicri:Area/Main/Merge">003118</idno><idno type="wicri:Area/Main/Curation">003049</idno><idno type="wicri:Area/Main/Exploration">003049</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">d-Penicillamine</title><author><name sortKey="Joyce, David A" sort="Joyce, David A" uniqKey="Joyce D" first="David A." last="Joyce">David A. Joyce</name></author></analytic><monogr></monogr><series><title level="j">Bailliere's Clinical Rheumatology</title><title level="j" type="abbrev">BACR</title><idno type="ISSN">0950-3579</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990">1990</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="553">553</biblScope><biblScope unit="page" to="574">574</biblScope></imprint><idno type="ISSN">0950-3579</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0950-3579</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Accessory function</term><term>Aldehyde groups</term><term>American academy</term><term>Annals</term><term>Antinuclear antibody</term><term>Arthritis</term><term>Aurothiomalate</term><term>Bioavailability</term><term>Biochemical pharmacology</term><term>Biological fluids</term><term>British journal</term><term>Cessation</term><term>Chronic therapy</term><term>Clinica chimica acta</term><term>Clinical investigation</term><term>Clinical pharmacology</term><term>Clinical response</term><term>Clinical rheumatology</term><term>Collagen</term><term>Collagen metabolism</term><term>Collagen synthesis</term><term>Complement component</term><term>Cooh</term><term>Disease activity</term><term>Dismute superoxide</term><term>Disulphide</term><term>Disulphides</term><term>Dixon</term><term>Dos</term><term>Drug metabolism</term><term>Drug reactions</term><term>Drug toxicity</term><term>Drug withdrawal</term><term>Erythematosus</term><term>Excretion</term><term>Experimental animals</term><term>Experimental conditions</term><term>Experimental immunology</term><term>Free radicals</term><term>Functional groups</term><term>Gold salts</term><term>Gravis</term><term>Haematuria</term><term>High doses</term><term>Hyaluronic acid</term><term>Idiopathic myasthenia gravis</term><term>Immune complexes</term><term>Immune system</term><term>Inflammatory</term><term>Inflammatory activity</term><term>Internal medicine</term><term>Lower doses</term><term>Lupus</term><term>Lymphocyte</term><term>Lymphocyte reaction</term><term>Metabolism</term><term>Monocyte</term><term>Multicenter</term><term>Multicenter trial group</term><term>Myasthenia</term><term>Myasthenia gravis</term><term>Natural history</term><term>Natural killer cells</term><term>Other causes</term><term>Oxygen species</term><term>Penicillamine</term><term>Penicillamine therapy</term><term>Peripheral blood</term><term>Pharmacokinetics</term><term>Pharmacology</term><term>Plasma albumin</term><term>Platelet count</term><term>Poor sulphoxidizers</term><term>Proteinuria</term><term>Pulmonary fibrosis</term><term>Radiological progression</term><term>Reactive</term><term>Reactive oxygen species</term><term>Relative bioavailability</term><term>Renal</term><term>Renal function</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatism</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid factor</term><term>Rheumatoid factors</term><term>Rheumatoid nodules</term><term>Rheumatology</term><term>Risk factors</term><term>Scandinavian journal</term><term>Sclerosis</term><term>Slow resolution</term><term>Sodium aurothiomalate</term><term>Soluble collagen</term><term>Sulphasalazine</term><term>Sulphoxidation status</term><term>Sulphydryl</term><term>Sulphydryl groups</term><term>Superoxide</term><term>Symmetrical disulphide</term><term>Syndrome</term><term>Synovial</term><term>Synovial fluid</term><term>Systemic lupus erythematosus</term><term>Systemic sclerosis</term><term>Taste disturbance</term><term>Therapy</term><term>Thiazolidine formation</term><term>Toxicity</term><term>Toxicity profile</term><term>Trace amounts</term><term>Transition metal</term><term>Untreated patients</term><term>Urinary excretion</term><term>Waring</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: d-Pen represents an effective treatment for a proportion of patients with RA and PSS. Its status in the treatment of juvenile RA is uncertain. The best results will be obtained by a skilful, careful physician maintaining careful surveillance for toxicity. Neither the mode of action nor the mechanisms of toxicity are well understood in RA. Consequently, safer and more effective analogues of d-pen have not been produced.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Joyce, David A" sort="Joyce, David A" uniqKey="Joyce D" first="David A." last="Joyce">David A. Joyce</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003049 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003049 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CD2F2E69A770DA328B3768D12AB0105EB2A00060
|texte= d-Penicillamine
}}
| This area was generated with Dilib version V0.6.33. |  |